Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CAH with free AI briefings, catalyst countdowns, and dilution alerts.

CAH · CARDINAL HEALTH INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.3B Cash on Hand
CF+ Cash Runway
Follow CAH by email Get an email when CAH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CAH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Chlorella Diabetes N/A · NCT01301287 Unknown
14-day Cerebrolysin treatment Intracerebral Hemorrhage Phase 4 · NCT06899464 Not yet recruiting
Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg… Galactose Single Point (GSP), Residual Liver Function Phase 1/2 · NCT04546022 Completed
Loxoprofen Pain Patch Delayed Onset Muscle Soreness Phase 2 · NCT02602353 Completed
Technetium Tc 99m-labeled Tilmanocept Anal Cancer Phase 2 · NCT02857608 Withdrawn
No Treatment Delayed Onset Muscle Soreness Phase 2 · NCT02602353 Completed
Isosulfan Blue Rhabdomyosarcoma Phase 2 · NCT02509598 Completed

Also used in these trials (approved or third-party drugs, not CAH's own candidates): Simvastatin, Empagliflozin, Cisplatin, Nivolumab, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CAH holds $5.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAH files for a raise →

👥 Who Owns CAH

Insiders 0.3% Institutions (2001 holders) 91.7% Public and other holders 8%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 17,635,857 7.63% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 13,786,683 5.96% 2026-03-31
Jason M. Hollar
Chief Executive Officer
Insider 190,603 0.08% 2026-08-18
Deborah Weitzman
CEO, PSS Segment
Insider 77,901 0.03% 2026-08-18
Gregory B Kenny
Director
Insider 64,194 0.03% 2025-11-05
Jessica L Mayer
Chief Legal/Compliance Officer
Insider 33,076 0.01% 2026-08-18
Patricia Hemingway Hall
Director
Insider 29,849 0.01% 2026-11-12
Nancy Killefer
Director
Insider 28,379 0.01% 2026-11-12
Akhil Johri
Director
Insider 22,869 0.01% 2026-11-12
Aaron E Alt
Chief Financial Officer
Insider 20,495 0.01% 2026-08-18
Stephen M Mason
CEO, GMPD Segment
Insider 18,061 0.01% 2026-08-18
David C Evans
Director
Insider 16,128 0.01% 2026-11-12

Share count 231,136,655 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CAH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.